Primary source: View
Labeling updates have been made to the Chenodeoxycholic acid Leadiant product information based on recent assessments regarding its safety and efficacy.
The labeling update ensures that healthcare providers have the latest information regarding the usage, benefits, and potential risks associated with Chenodeoxycholic acid Leadiant, especially given its orphan drug status.
Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.
Regulatory Intelligence Lead
Annual review
Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.
Chenodeoxycholic acid Leadiant, previously known as Chenodeoxycholic acid sigma-tau, has undergone a regulatory change following the summary of the European public assessment report which details its approval for use within the EU for treating cerebrotendinous xanthomatosis.
What changed: Labeling updates have been made to the Chenodeoxycholic acid Leadiant product information based on recent assessments regarding its safety and efficacy.
Why it matters: The labeling update ensures that healthcare providers have the latest information regarding the usage, benefits, and potential risks associated with Chenodeoxycholic acid Leadiant, especially given its orphan drug status.
Practical implication: Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.
Published from the regulator source ingestion pipeline after PV impact triage.
Review and verify that any cosmetic products sourced or distributed comply with the manufacturers listed in the updated QUEST system.
Health professionals and stakeholders should review the safety signals linked to CAROTONE products in their signal management processes.
Marketing authorization holders (MAHs) must review and potentially update their product labeling to align with the new regulations by 11 April 2029 for products authorized before 11 May 2024.
Regulatory Intelligence leads should initiate monitoring of feedback and prepare for potential regulatory adjustments related to the specified substances.
